LY-2300559

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H26O6
Molecular Weight	434.481
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1=C(O)C(=CC=C1OCC2=CC=C(C=C2)[C@H](O)C3=CC(=CC=C3)C(O)=O)C(C)=O

InChI

InChIKey=DWQVYDLTPMGYNE-DEOSSOPVSA-N

InChI=1S/C26H26O6/c1-3-5-22-23(13-12-21(16(2)27)25(22)29)32-15-17-8-10-18(11-9-17)24(28)19-6-4-7-20(14-19)26(30)31/h4,6-14,24,28-29H,3,5,15H2,1-2H3,(H,30,31)/t24-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H26O6
Molecular Weight	434.481
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.sciencedirect.com/science/article/pii/B9780123964922000060 | https://adisinsight.springer.com/drugs/800032738 | https://clinicaltrials.gov/ct2/show/NCT01184508

LY2300559 is a dual metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator and cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. Eli Lilly was developing LY2300559 for the prevention of migraine. LY2300559 development has been discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Metabotropic glutamate receptor 2 24 Target ID: Q14416 Gene ID: 2912.0 Gene Symbol: GRM2 Target Organism: Homo sapiens (Human) Sources: https://www.sciencedirect.com/science/article/pii/B9780123964922000060	Positive Allosteric Modulator 186		50.0 nM [EC50]
Cysteinyl leukotriene receptor 1 18 Target ID: Q9Y271 Gene ID: 10800.0 Gene Symbol: CYSLTR1 Target Organism: Homo sapiens (Human) Sources: https://www.sciencedirect.com/science/article/pii/B9780123964922000060	Antagonist 2849		22.0 nM [Ki]

PubMed

Title	Date	PubMed
Mechanism for enhanced absorption of a solid dispersion formulation of LY2300559 using the artificial stomach duodenum model.	2015-04-06	25723790

Sample Use Guides

In Vivo Use Guide

Phase 2 study in migraine prevention: 300 mg once daily, for 12 weeks

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:07:35 GMT 2025` Edited by `admin` on `Mon Mar 31 23:07:35 GMT 2025`
Record UNII	Z572ZBT8XL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LY-2300559

Common Name

English

LY2300559

Preferred Name

English

3-((S)-(4-((4-ACETYL-3-HYDROXY-2-PROPYL-PHENOXY)METHYL)PHENYL)-HYDROXY-METHYL)BENZOIC ACID

Systematic Name

English

BENZOIC ACID, 3-((S)-(4-((4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)METHYL)PHENYL)HYDROXYMETHYL)-

Systematic Name

English

Code System Code Type Description

FDA UNII

Z572ZBT8XL